主页 > 医学讨论 >
【medical-news】抗HIV药Prezista会引发肝炎
March 13, 2008 — Use of ritonavir-boosted darunavir (Prezista, Tibotec Therapeutics) has been linked to cases of hepatitis in clinical trials and postmarketing experience, the US Food and Drug Administration (FDA) warned healthcare professionals yesterday.
According to the revised labeling, drug-induced hepatitis (eg, acute hepatitis and cytolytic hepatitis) was reported in 0.5% of patients receiving darunavir/ritonavir during clinical trials. Patients with preexisting liver dysfunction, including active hepatitis B or C, are at increased risk for liver function abnormalities and severe hepatic adverse events.
Postmarketing cases of liver injury have generally occurred in patients with advanced HIV-1 infection taking multiple concomitant medications, having comorbidities such as hepatitis B or C coinfection, and/or developing immune reconstitution syndrome. The FDA notes that a causal role for darunavir/ritonavir has not been established.
Appropriate laboratory testing should be conducted before initiating darunavir/ritonavir therapy, and patients should be monitored during treatment, according to an alert issued by MedWatch, the FDA's safety information and adverse event reporting program. More frequent monitoring of liver enzymes may be indicated for patients with underlying chronic hepatitis, cirrhosis, or baseline transaminase elevations.
Interruption or discontinuation of therapy should be considered in patients with evidence of new or worsening liver dysfunction, as characterized by clinically significant increases in liver enzyme and/or symptoms such as fatigue, anorexia, nausea, jaundice, dark urine, liver tenderness, and hepatomegaly.
Darunavir is indicated for the treatment of HIV infection in antiretroviral treatment–experienced patients, such as those with HIV-1 strains resistant to more than 1 protease inhibitor. The drug's efficacy has not been determined in pediatric or treatment-naive patients.
http://www.medscape.com/viewarticle/571380 药物介绍
http://www.dxy.cn/portal/article/1/26/1578.html FDA官方警告
http://www.fda.gov/cder/drug/InfoSheets/HCP/darunavirHCP.htm
Information for Healthcare Professionals
Darunavir Ethalolate (marketed as Prezista)
--------------------------------------------------------------------------------
FDA ALERT [3/21/2008]: FDA is highlighting the addition of information about hepatotoxicity to the WARNINGS section of the Prezista prescribing information.
FDA and Tibotec Therapeutics have reviewed information from clinical trials in which Prezista was administered and from postmarketing adverse event reports of hepatotoxicity in patients taking Prezista. While causality is not firmly established, an association between Prezista and hepatotoxicity is suspected.
Prezista, a protease inhibitor indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, is co-administered with ritonavir, an antiretroviral drug associated with hepatotoxicity. In general, HIV antiretroviral medications are associated with liver enzyme elevations, however, for some medications, an association with hepatotoxicity is more firmly established.
Healthcare providers should conduct appropriate hepatic laboratory testing prior to and after starting patients on Prezista. Patients should promptly seek medical attention if they experience unexplained fatigue, anorexia, nausea, jaundice, abdominal pain or dark urine. Healthcare professionals should consider interrupting or discontinuing Prezista if evidence of new or worsening liver injury arises. 近日，美国食品药品管理局（FDA）和强生公司联合发布警告说，抗艾药Prezista可损害患者肝脏，甚至导致死亡。
强生Tibotec疗法部在FDA网站上表示，自2006年6月Prezista (darunavir)获批上市后，公司陆续收到肝损伤和死亡报告。参加临床试验的3063名患者中，有15名出现药物性肝炎。
然而，Tibotec还说明，发生肝损伤的患者大都是同时接受其它药物治疗的艾滋病晚期患者，以及慢性活动性乙型或丙型肝炎患者。慢性活动性乙型或丙型肝炎可加大肝损伤发生几率。Prezista是和雅培的Norvir (ritonavir)结合使用的，因此上述损伤和Prezista之间的因果关联并不能建立。
Tibotec称，医生在建议患者服用Prezista前需做测试，并不断监测患者肝酶水平。
摘自：http://www.chnmed.com/html/2008/0314/10373.html 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 New HIV Drug Linked to Risk for Hepatitis
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-05 17:20
医学,生命科学网